Fig. 17:  This Figure highlights results from a study^[16] that was not designed to evaluate rehospitalizations or discharge planning for patients with COPD, but rather was designed to see whether the addition of azithromycin to a COPD patient’s medical regimen reduced the occurrence of acute exacerbations.  The study randomized 1142 patients to either azithromycin 250 mg/day for 1 year or placebo.  The primary outcome was the time to the first acute exacerbation of COPD once the patients started the medication or placebo.